Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Summary

This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).

Timeline

Start

2016-11-29

Primary completion

2023-11-29

Completion

2024-11-14

Publications

• Cutler C, Kim HT, El Banna H, Halloran E, Matozel E, Ho VT, Koreth J, Gooptu M, Shapiro R, Kelkar A, Gibson C, Nikiforow S, Nageshwar P, Reynolds C, Ansuinelli M, Tamada R, Au C, Panaro K, Gervais C, DeFilipp Z, El-Jawahri A, Chen YB, El Jurdi N, Weisdorf D, Couriel D, Lee C, Arai S, Sahaf B, Bacigalupi J, Ji K, Soiffer R, Miklos D, Antin JH, Ritz J. Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease. J Clin Oncol. 2026 Jun;44(16):1529-1539. doi: 10.1200/JCO-25-03104. Epub 2026 Apr 30.

Drugs

Indications